Pages that link to "Q37382208"
Jump to navigation
Jump to search
The following pages link to Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives (Q37382208):
Displaying 6 items.
- Indications and safety of intravenous and subcutaneous immunoglobulin therapy (Q37877259) (← links)
- Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex. (Q42257925) (← links)
- Combination of FVIII and by‐passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma (Q45864409) (← links)
- Regulatory B Cells Are Functionally Impaired in Patients Having Hemophilia A With Inhibitors. (Q45866611) (← links)
- A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate (Q45876345) (← links)
- Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein (Q45882083) (← links)